• Elon Musk’s company, Neuralink has secured $650 million in funding during the Series E financing round.
• The Series E round gathered the support of many leading investors from DFJ Growth, ARK Invest, Founders Fund, and Human Capital.
• Neuralink is performing clinical trials at famous neurosurgical facilities in three countries on two continents to validate its procedures further.

Elon Musk’s company Neuralink, has secured $650 million in funding during the Series E financing round, marking a significant success for its ambition to modernize implantable brain technology. The boost of 200 million dollars, which was revealed on June 03, 2025, aims to improve Neuralink’s devices and help individuals affected by conditions such as paralysis and speech damage gain their independence.

The Series E round gathered the support of many leading investors from DFJ Growth, ARK Invest, Founders Fund, Human Capital, G42, Lightspeed, QIA, Thrive Capital, Sequoia Capital, Valor Equity Partners and Vy Capital. Support from a wide group highlights the belief in Neuralink’s ability to change the way neuroscience and technology is connected. After receiving funding with the Series D round in August 2023, the company has advanced a lot in making brain interfaces that users can use to connect with both digital and real-world sensors.

Currently, five people with severe paralysis are now using Neuralink technology to control a range of devices in real life. Neuralink is performing clinical trials at famous neurosurgical facilities in three countries on two continents to validate its procedures further. These include the Miami Project to Cure Paralysis at the University of Miami, US, the Barrow Neurological Institute, US, the Cleveland Clinic Abu Dhabi, and the University Health Network Canada.

Also Read: Microsoft to Invest $400M in Switzerland for AI, Cloud Expansion

Because of new funding, Neuralink aims to boost its device’s ability to affect more neurons and brain spots which could offer new ways to use it. It reflects the company’s goal to unify biological intelligence with artificial intelligence and develop leading answers. In November 2024, Neuralink received approval for the CONVOY trial, which explores the brain implant alongside an assistive robotic arm, complementing the ongoing PRIME study in the US

Additionally, Health Canada greenlit the CAN-PRIME trial, Neuralink’s first global study, with the University Health Network as a key site. Recently, the US FDA granted breakthrough device designation for treating severe speech impairment.